Major Depressive Disorder Study In Adults

• Status: Completed
• Trial end date: 2003-09-01
• Target enrollment: 0
• Participant gender: All

Summary

A study to obtain safety and tolerability data

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Paroxetine; Serotonin Uptake Inhibitors

Criteria

Inclusion Criteria:

• Patient must have primary diagnosis of Major Depressive Disorder (MDD).

• Discontinued a selective serotonin reuptake inhibitor (SSRI)or serotonin-norepinephrine reuptake inhibitor (SNRI) regimen due to intolerability.

• Minimum time frame between last dose of previous antidepressant and initiation of study drug is one week.

• Maximum time frame between last dose of prior antidepressant and initiation of study drug is 2 months.

Exclusion Criteria:

• Patient has previously been treated with the study drug.

• Is experiencing an adverse event attributed to previous SSRI/SNRI use that has not been resolved at least one week prior to Baseline Visit.

• Has a history of seizure disorder.

• Has met criteria for substance abuse or dependence within 6 months prior to Baseline Visit.

• Currently using an antidepressant.

• Currently pregnant.